Nov 21, 2023
The former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase. BRAINTREE, Mass. , Nov. 21, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc.
Nov 13, 2023
The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with the FDA BRAINTREE, Mass. , Nov. 13, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Robotic Surgical System, today
Nov 08, 2023
BRAINTREE, Mass. , Nov. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic system, today announced it had been granted a registered trademark from the US Patent and Trademark Office .
Oct 31, 2023
Follow up visual examination three days after the procedures using the LIBERTY Robotic Surgical System, confirms 100% success rate in reaching the targets with no adverse events BRAINTREE, Mass. , Oct. 31, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc.
Oct 24, 2023
The Company’s designated   N otified B ody confirmed dates for conducting audits for ISO 13485 certification to ensure Microbot complies with the QMS requirements of the EU MDR The Company expects that t he full   CE Mark a pproval process of obtaining clearance of sales in the European Union for
Oct 19, 2023
BRAINTREE, Mass. , Oct. 19, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Robotic Surgical System, today announces that the United States District Court for the Southern District of New York , approved Microbot’s motion for summary judgment and
Oct 17, 2023
A total of 48 animal targets were reached with 100% usability and technical success and no visual acute intra-operative adverse events or complications This pivotal study , together with the verification and validation stud ies , is expected to serve as the basis for the IDE submission to the FDA
Sep 27, 2023
The engagement is an additional step in the Company's path towards marketing clearance with the FDA BRAINTREE, Mass. , Sept. 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic system,
Sep 08, 2023
The presentation follows successful extensive uses of the Company’s endovascular robotic system in pre-clinical studies BRAINTREE, Mass. , Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY ®

Displaying 19 - 27 of 158

Search Investor Relations